Mitomicina C tópica endotraqueal como terapia complementaria al tratamiento endoscópico de la estenosis laringotraqueal fibrótico-cicatricial recurrente / Topical endotracheal mitomycin C as a complementary treatment for endoscopic treatment of recurrent laryngotracheal stenosis

Objetivo Describir la preparación de mitomicina C tópica endotraqueal y los resultados clínicos de 4 pacientes tratados de forma coadyuvante con mitomicina C tópica para estenosis laringotraqueales (ELT) graves y recurrentes. Método Revisión bibliográfica para determinar la concentración y forma de elaboración de mitomicina C para uso tópico endotraqueal. Revisión de las historias clínicas. Resultados Se determina una concentración de 0,4mg/ml mitomicina C tópica en el tratamiento de las estenosis laringotraqueales. En los casos tratados se aplicó la solución de 0,4mg/ml en la zona estenosada tras fotorresección con láser y dilatación con broncoscopio. Tres pacientes se encuentran asintomáticos desde el punto de vista respiratorio y en uno, ha fracasado el tratamiento. Conclusiones El tratamiento ELT es complejo debido al continuo desarrollo de tejido de granulación y fibrosis como consecuencia de lesiones de la vía aérea. La mitomicina C tópica, por sus potentes efectos antifibróticos, parece ser el agente coadyuvante idóneo (AU)

Objective To describe the preparation of topical endotracheal mitomycin C and the clinical outcomes of four patients with recurrent and severe laryngotracheal stenosis (LTS) treated with adjuvant topical mitomycin C. Method Literature review to determine the concentration and method of preparation of topical mitomycin C for endotracheal use. Review of clinical histories. Results We established a concentration of 0.4mg/ml topical mitomycin C for the treatment of laryngotracheal stenosis. In the treated cases, we applied a 0.4mg/ml solution to the wound site following laser surgery and dilatation with bronchoscope. Three patients remain asymptomatic from a respiratory perspective, and treatment failed in one case. Conclusions LTS treatment is complex due to the continuous development of granulation tissue and fibrosis following injury to the airways. Topical mitomycin C seems to be the ideal adjuvant agent thanks to its powerful antifibrotic effects (AU)

Topical endotracheal mitomycin C as a complementary treatment for endoscopic treatment of recurrent laryngotracheal stenosis.

OBJECTIVE: To describe the preparation of topical endotracheal mitomycin C and the clinical outcomes of four patients with recurrent and severe laryngotracheal stenosis (LTS) treated with adjuvant topical mitomycin C. METHOD: Literature review to determine the concentration and method of preparation of topical mitomycin C for endotracheal use. Review of clinical histories. RESULTS: We established a concentration of 0.4 mg/ml topical mitomycin C for the treatment of laryngotracheal stenosis. In the treated cases, we applied a 0.4 mg/ml solution to the wound site following laser surgery and dilatation with bronchoscope. Three patients remain asymptomatic from a respiratory perspective, and treatment failed in one case. CONCLUSIONS: LTS treatment is complex due to the continuous development of granulation tissue and fibrosis following injury to the airways. Topical mitomycin C seems to be the ideal adjuvant agent thanks to its powerful antifibrotic effects.